Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...

That “waste-to-value” is increasingly getting quiet attention from private equity and infrastructure investors.

Wall Street is often blamed for reducing corporate managers’ understanding of business to a single, gameable measure of ...

Wall Street is still awaiting regulatory approval for the first full-blown private-asset ETFs, but for now opportunistic ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Trump opened the door for private equity to tap 401(k)s, and now private equity bosses want legal protection. Here's what ...

Private-equity executives entered 2025 with high hopes for a dealmaking recovery that is lifting payouts to fund investors ...

In 2025’s go-go leveraged debt markets, everything is up for negotiation, but a trio of investor protections are proving to ...

Successful firms are increasingly split between behemoths with several business lines and those focusing on their roots of ...

As stakeholders recalibrate their approaches, secondaries offer a proving ground for innovative capital strategies that could influence private equity far into the future.

Last month, a deal for Sycamore Partners to buy pharmacy chain Walgreens was seen as “mostly dead,” but reports say it may ...

In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...